1005484-24-1

Basic information

• Product Name: 1,4-di-tert-butyl 7-(2-{[(tert-butoxy)carbonyl]amino}-3-(4-nitrophenyl)propyl)-1,4,7-triazonane-1,4-dicarboxylate
• Synonyms: 1,4-di-tert-butyl 7-(2-{[(tert-butoxy)carbonyl]amino}-3-(4-nitrophenyl)propyl)-1,4,7-triazonane-1,4-dicarboxylate
• CAS NO: 1005484-24-1
• Molecular Weight: 607.748
• Mol File: 1005484-24-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1,4-di-tert-butyl 7-(2-{[(tert-butoxy)carbonyl]amino}-3-(4-nitrophenyl)propyl)-1,4,7-triazonane-1,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-di-tert-butyl 7-(2-{[(tert-butoxy)carbonyl]amino}-3-(4-nitrophenyl)propyl)-1,4,7-triazonane-1,4-dicarboxylate(1005484-24-1)
• EPA Substance Registry System: 1,4-di-tert-butyl 7-(2-{[(tert-butoxy)carbonyl]amino}-3-(4-nitrophenyl)propyl)-1,4,7-triazonane-1,4-dicarboxylate(1005484-24-1)

Safety Data

• Hazardous Substances Data: 1005484-24-1(Hazardous Substances Data)

Upstream product

• 1258945-86-6 tert-butyl N-[1-(4-nitrophenyl)-3-oxopropan-2-yl]carbamate 
• 174138-01-3 1,4-di-tert-butyl 1,4,7-triazonane-1,4-dicarboxylate 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 58966-93-1 1,4,7-triazacyclononane trihydrochloride 
• 114346-29-1 tert-butyl N-[(2S)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl]carbamate 
• 183669-13-8 tert-butyl (1-hydroxy-3-(4-nitrophenyl)propan-2-yl)carbamate 
• 1005484-23-0 tert-butyl 2-(4-nitrobenzyl)aziridine 1-carboxylate 

Downstream Products

• 1005484-25-2 1-(4-nitrobenzyl)-2-(1,4,7-triazacyclononan-1-yl)ethylamine 
• 1041634-48-3 C₃₉H₆₇N₅O₈ 
• 1005484-26-3 tert-butyl {4-[2-(bis-(tert-butoxycarbonylmethyl)amino)-3-(4-nitrophenyl)propyl]-7-tert-butoxycarbonylmethyl[1,4,7]triazanonan-1-yl}acetate 
• 1041634-52-9 {4-carboxymethyl-7-[2-(carboxymethyl-amino)-3-(4-isothiocyanato-phenyl)-propyl]-[1,4,7]-triazonan-1-yl}-acetic acid 
• 1173056-35-3 2-[(1-{4-[(4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-5-amino-9,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl]pentanamido]phenyl}-3-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]propan-2-yl)amino]acetic acid 
• 1173056-38-6 2-({1-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]-3-{4-[(4R)-4-[(1S,2S,5R,7S,9R,10R,11S,14R,15R,16S)-9,16-dihydroxy-2,15-dimethyl-5-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]tetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl]pentanamido]phenyl}propan-2-yl}amino)acetic acid 
• 1173056-20-6 [4-carboxymethyl-7-(2-(carboxymethyl-amino)-3-{4-[(R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]phenyl}-propyl)-[1,4,7]triazonan-1-yl]-acetic acid 
• 1173056-18-2 [4-carboxymethyl-7-(2-(carboxymethyl-amino)-3-{4-[(R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-phenyl}-propyl)-[1,4,7]triazonan-1-yl]-acetic acid 
• 1173056-12-6 [4-tert-butoxycarbonylmethyl-7-(2-(tert-butoxycarbonyl methyl-amino)-3-{4-[(R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-phenyl}-propyl)-[1,4,7]triazonan-1-yl]-acetic acid tert-butyl ester 
• 1173056-11-5 [4-tert-butoxycarbonylmethyl-7-(2-(tert-butoxycarbonylmethyl-amino)-3-{4-[(R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-phenyl}-propyl)-[1,4,7]triazonan-1-yl]-acetic acid tert-butyl ester 
• 1041634-50-7 {4-[3-(4-amino-phenyl)-2-(carboxymethyl-amino)-propyl]-7-carboxymethyl-[1,4,7]triazonan-1-yl}-acetic acid 
• 1016237-83-4 tert-butyl {4-[3-(4-amino-phenyl)-2-(tert-butoxycarbonylmethyl-amino)-propyl]-7-tert-butoxycarbonylmethyl-[1,4,7]triazonan-1-yl}-acetate 
• 1016237-90-3 {4-carboxymethyl-7-[2-(carboxymethyl-amino)-3-(4-nitro-phenyl)-propyl]-[1,4,7]-triazonan-1-yl}-acetic acid 
• 1029127-63-6 t-butyl [4-tert-butoxycarbonylmethyl-7-(2-(tert-butoxycarbonylmethyl-amino)-3-{4-[(R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoylamino]-phenyl}-propyl)-[1,4,7]-triazonan-1-yl]acetate 

Relevant articles and documents

COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY

Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

Synthesis and Evaluation of an Enantiomerically Enriched Bifunctional Chelator for 64Cu-Based Positron Emission Tomography (PET) Imaging

We report the synthesis and evaluation of an enantiomerically enriched bifunctional chelator, (S)-C-NE3TA. The bifunctional chelator was efficiently prepared by regioselective and stereoselective ring opening of an aziridinium ion. The new chiral chelator instantly and almost completely bound to 64Cu at room temperature. The corresponding 64Cu-radiolabeled complex remained intact in human serum for 48 h without any measurable transchelation and was tolerant to a rigorous EDTA challenge for 24 h. The 64Cu-radiolabeled (S)-C-NE3TA complex was stable in mice and produced an excellent biodistribution profile. The results of the in vitro and in vivo evaluations indicate that the new optically active chelator is a promising candidate for PET imaging applications.

Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy

An antibody-targeted radiation therapy (radioimmunotherapy, RIT) employs a bifunctional ligand that can effectively hold a cytotoxic metal with clinically acceptable complexation kinetics and stability while being attached to a tumor-specific antibody. Clinical exploration of the therapeutic potential of RIT has been challenged by the absence of adequate ligand, a critical component for enhancing the efficacy of the cancer therapy. To address this deficiency, the bifunctional ligand C-NETA in a unique structural class possessing both a macrocyclic cavity and a flexible acyclic moiety was designed. The practical, reproducible, and readily scalable synthetic route to C-NETA was developed, and its potential as the chelator of 212Bi, 213Bi, and 177Lu for RIT was evaluated in vitro and in vivo. C-NETA rapidly binds both Lu(III) and Bi(III), and the respective metal complexes remain extremely stable in serum for 14 days. 177Lu-C-NETA and 205/6Bi-C-NETA possess an excellent or acceptable in vivo biodistribution profile.